Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow

Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow
复制标题

DOI:
10.1634/stemcells.2006-0709
复制
发表时间:
2007-06-01
期刊:
影响因子:
5.2
通讯作者:
Tuan, Rocky S.
Tuan, Rocky S.
中科院分区:
医学2区
文献类型:
--
作者:
Baksh, Dolores;Yao, Raphael;Tuan, Rocky S.

文献摘要

被引文献

相似文献

人脐带血管周细胞(HUCPVCs)已被证明具有高增殖潜力和分化成骨表型的能力。因此,HUCPVC被认为是细胞疗法的可能的胚外间充质干细胞(MSC)来源。为了评估这种潜力,我们将HUCPVCs与“金标准”骨髓间充质基质细胞(BMSC)的增殖、分化和转染能力进行了比较。HUCPVCs表现出比BMSCs更高的增殖潜力,并且能够成骨、成软骨和成脂分化。有趣的是,HUCPVCs的成骨分化比BMSCs进行得更快。此外,HUCPVCs表达更高水平的CD146,一个假定的MSC标记物,相对于BMSC。使用核转染方法,HUCPVC显示出与BMSC相当的转染效率,但更适合用脂质体方法(FuGENE)转染。基因阵列分析表明,HUCPVCs也表达Wnt信号通路基因,这些基因与MSC的调控有关。HUCPVC和MSC之间的相似特征支持HUCPVC用于基于细胞的疗法的适用性。
Human umbilical cord perivascular cells (HUCPVCs) have been shown to have a high proliferative potential and the capacity to differentiate into an osteogenic phenotype. HUCPVCs have thus been considered a possible extra-embryonic mesenchymal stem cell (MSC) source for cell-based therapies. To assess this potential, we compared HUCPVCs to the "gold standard" bone marrow mesenchymal stromal cells (BMSCs) with respect to their proliferation, differentiation, and transfection capacities. HUCPVCs showed a higher proliferative potential than BMSCs and were capable of osteogenic, chondrogenic, and adipogenic differentiation. Interestingly, osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs. Additionally, HUCPVCs expressed higher levels of CD146, a putative MSC marker, relative to BMSCs. HUCPVCs showed comparable transfection efficiency as BMSCs using a nucleofection method but were more amenable to transfection with liposomal methods (FuGENE). Gene array analysis showed that HUCPVCs also expressed Wnt signaling pathway genes that have been implicated in the regulation of MSCs. The similar characteristics between HUCPVCs and MSCs support the applicability of HUCPVCs for cell-based therapies.